Australia To Consider Removal Of Popular Painkiller From OTC
This article was originally published in PharmAsia News
Executive Summary
Australia authorities are considering a move to remove over-the-counter status for one of the country's favorite painkillers, Nurofen's Nurofen Plus (ibuprofen, codeine phosphate). An advisory panel has set a June meeting to consider the proposal to move Nurofen Plusand similar painkillers containing codeine to prescription-only status. Physician and pharmacy groups say the move is too drastic and suggest an alternative could be limiting the size of packets of the drugs. The nation's leading medical journal reported misuse of such drugs, particularly Nurofen Plus, is a significant problem in the country. (Click here for more
You may also be interested in...
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.
First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar
Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.